Full Press Release Details
Phone: (410) 269-2610
PHARMATHENE REPORTS YEAR-END 2013
FINANCIAL AND OPERATIONAL RESULTS
ANNAPOLIS, MD - March 11, 2014
- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and
chemical threats, today reported its financial and operational results for the year ended December 31, 2013.
"We remain focused on advancing our
core biodefense programs, including addressing the SparVax clinical hold which is our top priority," said
Eric I. Richman, President and Chief Executive Officer. "We have a clear path forward based on comments from the U.S. Food
and Drug Administration (FDA), which includes manufacturing a new clinical lot for use in the proposed study. At the same time,
we are looking forward to a decision from the Delaware Chancery Court in the next several months regarding our ongoing litigation
with SIGA Technologies."
Linda L. Chang, Senior Vice President and
Chief Financial Officer, commented, "Aside from one-time merger transaction costs in 2013, our cash usage continues to be
manageable. We will continue to deploy our resources efficiently while we work to secure additional U.S. government funding and
await the outcome of the SIGA litigation."
Year-End 2013 Financial Results
For the year ended December 31, 2013, PharmAthene
recognized revenue of $17.9 million, compared to $25.2 million in 2012. Revenue in 2013 and 2012 was derived from development contracts
with the U.S. government for development of the Company's biodefense product candidates. The reduction in revenue in 2013
reflects decreased development activity in the SparVax anthrax vaccine program as a result of two FDA clinical
holds imposed in August 2012 and December 2013, along with a temporary suspension of work as a result of the partial federal government
shutdown, which occurred October 1st through October 16th, 2013. Consequently, revenue for the SparVax program
was lower in 2013 than in previous years.
Research and development expenses in 2013
were $15.3 million, compared to $19.5 million in 2012. Research and development expenses in 2013 declined primarily as a result
of decreased activity in the SparVax anthrax vaccine program. In addition, the Company received a vendor lawsuit
settlement of $0.5 million, which was recorded as a reduction in research and development expenses. The reduction in costs for
SparVax were partially offset by increased costs for the bioscavenger program.
Expenses associated with general and administrative
functions were $13.3 million in 2013, compared to $11.6 million in 2012. The increase in general and administrative costs was due
to approximately $3.3 million in merger transaction costs associated with the proposed merger with Theraclone Sciences, Inc., which
was terminated in December 2013.
For the year ended December 31, 2013, PharmAthene
recorded other expense of $0.8 million compared to other income of $1.5 million in 2012. During 2012, PharmAthene substantially
liquidated PharmAthene Canada, Inc., and realized the $1.2 million gain from the cumulative translation adjustment in the current
For the year ended December 31, 2013, PharmAthene's
net loss was $11.7 million, or $0.23 per share, compared to a net loss of $4.9 million, or $0.10 per share, for the year ended
December 31, 2012. The increase in net loss is due to an increase in the loss from operations of $4.5 million, discussed above.
PharmAthene also realized a $2.4 million decrease in other income for 2013 compared to 2012. The 2012 income included a gain of
$1.2 million associated with the cumulative translation adjustment recorded to earnings for the substantial liquidation of PharmAthene
Canada, Inc. There was also a $1.0 million change in the re-measurement of the fair value of the derivative instruments from 2012
Cash and Accounts Receivable
As of December 31, 2013, the Company had
cash and cash equivalents totaling approximately $10.5 million, compared to $12.7 million as of December 31, 2012. U.S. government
billed and unbilled accounts receivable totaled approximately $3.6 million at December 31, 2013 compared to $6.5 million at December
31, 2012. The decrease in receivables is related to a reduction in product development activity during 2013. The sum total of cash
and cash equivalents and U.S. government accounts receivable at December 31, 2013 was approximately $14.1 million, compared to
$19.2 million at December 31, 2012.
Conference Call and Webcast Information
PharmAthene management will be hosting
a conference call to discuss the Company's year-end 2013 financial and operational results. The call is scheduled to begin
at 4:30 p.m. Eastern Time on Tuesday, March 11, 2014 and is expected to last approximately 30 minutes. The dial-in number within
the United States is 866-318-8616. The dial-in number for international callers is 617-399-5135. The participant passcode is 64114055.
A replay of the conference call will be
available beginning at approximately 8:30 p.m. Eastern Time on March 11, 2014 until approximately 11:59 p.m. Eastern Time on April
11, 2014. The dial-in number to access the replay from within the United States is 888-286-8010. For international callers, the
dial-in number is 617-801-6888. The participant passcode is 76960661.
The conference call will also be webcast
and can be accessed from the Company's website at www.PharmAthene.com. A link to the webcast may be found under the Investor
Relations section of the website.
PharmAthene is a leading biodefense company
engaged in the development and commercialization of next generation medical countermeasures against biological and chemical threats.
PharmAthene's current biodefense portfolio includes the following product candidates:
In addition, in May 2013, the Delaware
Supreme Court issued its ruling on the appeal in our litigation with SIGA Technologies, affirming the Court of Chancery's
finding that SIGA was liable for breach of contract, reversing its finding of promissory estoppel, and remanding the case back
to the Court of Chancery to reconsider the appropriate remedy and award of attorney's fees and expert witness costs in light of
the Supreme Court's opinion. For more information about PharmAthene, please visit www.PharmAthene.com.
Forward-Looking Statement Disclaimer
Except for the historical information presented
herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future
results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including
statements preceded by, followed by, or that include the words "will"; "potential"; "believe";
"anticipate"; "look forward"; "intend"; "plan"; "expect"; "estimate";
"could"; "may"; "should"; or similar statements are forward-looking statements. Such statements include,
but are not limited to those referring to the outcome of the SIGA litigation and our ability to deploy our resources. PharmAthene
disclaims any intent or obligation to update these forward-looking statements. Risks and uncertainties include, among others, risks
associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from
the company's product candidates; unexpected funding delays and/or reductions or elimination of U.S. government funding for one
or more of the company's development programs; awards of government contracts to our competitors; unforeseen safety issues; unexpected
determinations that these product candidates prove not to be effective and/or capable of being marketed as products; as well as
risks detailed from time to time in PharmAthene's Form 10-K and quarterly reports on Form 10-Q under the caption "Risk Factors"
and in its other reports filed with the U.S. Securities and Exchange Commission. In particular, there is significant uncertainty
regarding the level and timing of sales of Arestvyr and whether and when it will be approved by the U.S. FDA and corresponding
health agencies around the world. PharmAthene cannot predict with certainty if or when SIGA will begin recognizing profit on the
sale thereof and there can be no assurance that any profits received by SIGA will be significant. In its May 2013 decision, the
Delaware Supreme Court reversed the remedy ordered by the Delaware Court of Chancery and remanded the issue of a remedy back to
the trial court for reconsideration in light of the Delaware Supreme Court's opinion. As a result, there can be no assurance
that the Delaware Chancery Court will issue a remedy that provides PharmAthene with a financial interest in Arestvyr and
related products or any remedy. In addition, significant additional research work, non-clinical animal studies, clinical trials,
and manufacturing development work remains to be done with respect to PharmAthene's product candidates. At this point, there
can be no assurance that any of these product candidates will be shown to be safe and effective and approved by regulatory authorities
for use in humans. Copies of PharmAthene's public disclosure filings are available from its investor relations department and its
website under the investor relations tab at www.pharmathene.com.
CONSOLIDATED BALANCE SHEETS
| December 31, | ||||||||
| 2013 | 2012 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 10,480,979 | $ | 12,701,517 | ||||
| Accounts receivable (billed) | 1,427,113 | 2,432,641 | ||||||
| Unbilled accounts receivable | 2,199,525 | 4,114,442 | ||||||
| Prepaid expenses and other current assets | 231,491 | 547,245 | ||||||
| Total current assets | 14,339,108 | 19,795,845 | ||||||
| Property and equipment, net | 386,068 | 483,976 | ||||||
| Other long-term assets and deferred costs | 65,660 | 113,130 | ||||||
| Goodwill | 2,348,453 | 2,348,453 | ||||||
| Total assets | $ | 17,139,289 | $ | 22,741,404 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,128,172 | $ | 1,697,280 | ||||
| Accrued expenses and other liabilities | 3,182,687 | 2,328,877 | ||||||
| Deferred revenue | 341,723 | 1,381,755 | ||||||
| Short-term debt | 1,091,740 | 1,330,507 | ||||||
| Current portion of derivative instruments | 51,663 | - | ||||||
| Current portion of long-term debt | 999,996 | 749,997 | ||||||
| Total current liabilities | 6,795,981 | 7,488,416 | ||||||
| Other long-term liabilities | 588,745 | 579,427 | ||||||
| Long-term debt, less current portion | 730,279 | 1,704,108 | ||||||
| Derivative instruments, less current portion | 1,688,572 | 1,295,613 | ||||||
| Total liabilities | 9,803,577 | 11,067,564 | ||||||
| Stockholders' equity: | ||||||||
| Common stock, $0.0001 par value; 100,000,000 shares authorized; 52,304,246 and 48,352,651 shares issued and outstanding at December 31, 2013 and 2012, respectively | 5,230 | 4,835 | ||||||
| Additional paid-in-capital | 217,877,117 | 210,495,905 | ||||||
| Accumulated other comprehensive loss | (218,710 | ) | (217,328 | ) | ||||
| Accumulated deficit | (210,327,925 | ) | (198,609,572 | ) | ||||
| Total stockholders' equity | 7,335,712 | 11,673,840 | ||||||
| Total liabilities and stockholders' equity | $ | 17,139,289 | $ | 22,741,404 |
| PHARMATHENE, INC. | ||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||
| Year Ended December 31, | ||||||||||||
| 2013 | 2012 | 2011 | ||||||||||
| Contract Revenue | $ | 17,912,607 | $ | 25,175,887 | $ | 24,266,274 | ||||||
| Operating expenses: | ||||||||||||
| Research and development | 15,290,142 | 19,509,629 | 21,219,853 | |||||||||
| General and administrative | 13,279,186 | 11,628,732 | 14,311,079 | |||||||||
| Depreciation | 182,487 | 303,916 | 461,073 | |||||||||
| Total operating expenses | 28,751,815 | 31,442,277 | 35,992,005 | |||||||||
| Loss from operations | $ | (10,839,208 | ) | $ | (6,266,390 | ) | $ | (11,725,731 | ) | |||
| Other income (expense): | ||||||||||||
| Interest income | 2,575 | 17,808 | 16,660 | |||||||||
| Interest expense | (369,281 | ) | (342,561 | ) | (54,573 | ) | ||||||
| Gain on the sale of assets held for sale | - | - | 781,760 | |||||||||
| Realization of cumulative translation adjustment | - | 1,227,656 | - | |||||||||
| Change in fair value of derivative instruments | (444,622 | ) | 591,039 | 7,144,983 | ||||||||
| Other income (expense) | (6,071 | ) | 47,862 | 39,328 | ||||||||
| Total other income (expense) | (817,399 | ) | 1,541,804 | 7,928,158 | ||||||||
| Net loss before provision for income taxes | (11,656,607 | ) | (4,724,586 | ) | (3,797,573 | ) | ||||||
| Provision for income taxes | (61,746 | ) | (195,529 | ) | - | |||||||
| Net Loss | $ | (11,718,353 | ) | $ | (4,920,115 | ) | $ | (3,797,573 | ) | |||
| Basic and diluted net loss per share | $ | (0.23 | ) | $ | (0.10 | ) | $ | (0.08 | ) | |||
| Weighted average shares used in calculation of basic and diluted net loss per share | 50,659,116 | 48,323,067 | 47,331,763 |